Standardization and clinical implementation of liquid biopsy assays - IMI's CANCER-ID

Pantel, Klaus; Terstappen, Leon W. M. M.; manaresi, nicolo; Groen, Harry J. M.; Tamminga, Menno; Schuuring, Eduardus; Heitzer, Ellen; Speicher, Michael R.; Naume, Bjorn; kyte, jon amund

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Publication date:
2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
The academic leaders of CANCER-ID, Professor Klaus Pantel (UKE, Germany), who has experience with mid-sized enterprises (SME), and pharmaceutical and diagnostic companies established the CANCER-ID consortium (www.cancer-id.eu) is a five-year (2015-2019) international public-private partnership project supported by Europe’s Innovative Medicines Initiative (IMI). The CANCER-ID consortium is funded by IMI (Agreement n° 115749, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 2015-H2-FP7-922308) and companies (Bayer AG, Genentech, Inc., Genomic Health, Inc., and Sanofi-Aventis). The CANCER-ID consortium is currently planning an international clinical trial (NCT03409198) on the establishment of harmonized best practice protocols for patient sample collection, operating procedures (SOPs) and scientific support of liquid biopsy proficiency testing. For additional information please contact Prof. Klaus Pantel (pantel@uke.de).

The CANCER-ID consortium is currently planning an international clinical trial (NCT03409198) on the establishment of harmonized best practice protocols for patient sample collection, operating procedures (SOPs) and scientific support of liquid biopsy proficiency testing. For additional information please contact Prof. Klaus Pantel (pantel@uke.de).

The CANCER-ID consortium is currently planning an international clinical trial (NCT03409198) on the establishment of harmonized best practice protocols for patient sample collection, operating procedures (SOPs) and scientific support of liquid biopsy proficiency testing. For additional information please contact Prof. Klaus Pantel (pantel@uke.de).

The CANCER-ID consortium is currently planning an international clinical trial (NCT03409198) on the establishment of harmonized best practice protocols for patient sample collection, operating procedures (SOPs) and scientific support of liquid biopsy proficiency testing. For additional information please contact Prof. Klaus Pantel (pantel@uke.de).